TLRY
Aphria Q3 2019 Earnings Review – Headlines Create Opportunity
Aphria (TSE: APHA) posted messy quarterly results but remains an undervalued name with big revenue potential later in 2019.
Organigram 2Q 2019 Earnings Review – Selling Cannabis Customers Want
Organigram (CVE: OGI) posted another strong quarter. As a smaller producer, their cannabis production capabilities are impressive and undervalued.
Canadian Cannabis Scorecard (Spring 2019)
Confused about which marijuana stocks are worth your money? The Canadian Cannabis Scorecard is your guide to separating the best…
Tilray Subsidiary Natura Naturals Granted Expanded License From Health Canada
Gearing up for the expected nationwide legalization of edible cannabis products this coming October, a recent Tilray, Inc. (NASDAQ: TLRY) acquisition was…
Cronos Q4 2018 Earnings Review – The New Most Expensive Stock in Cannabis
In Cronos' (TSX: CRON) latest earnings report, they both grabbed the crown for most expensive cannabis company and disappointed with…
Tilray Q4 2018 Earnings – Eye Watering Stock Price Hard to Justify
Bottom Line This is likely a quarter Tilray's management wants to forget. Revenue of C$20.9 million missed even the low…
Tilray Taps Goldman Sachs Exec For Chief Corporate Development Officer
Seeking to widen the company’s global leadership team with new members, Tilray Inc. (NASDAQ: TLRY) looked to the financial industry this week…
HEXO Q2 2019 Earnings – On the Edge of Profitability
A full review of HEXO (TSE: HEXO) Q2 2019 earnings. Should you buy this value priced name or are there…
Tilray Set to Double Portuguese Workforce
Tilray (NASDAQ:TLRY) has announced plans to double its workforce in Portugal to 200 as it plans to boost production in…